Provided by Tiger Trade Technology Pte. Ltd.

Alpha Tau Medical

14.92
+0.56003.90%
Post-market: 14.950.0300+0.20%19:48 EDT
Volume:626.16K
Turnover:9.28M
Market Cap:1.38B
PE:-14.19
High:15.02
Open:14.57
Low:14.40
Close:14.36
52wk High:15.02
52wk Low:3.06
Shares:92.33M
Float Shares:63.79M
Volume Ratio:1.47
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0517
EPS(LYR):-0.5300
ROE:-141.68%
ROA:-25.71%
PB:31.27
PE(LYR):-28.15

Loading ...

Alpha Tau Medical - to Resume Recruitment for Remaining Seven Patients in Regain Trial

THOMSON REUTERS
·
Jun 11

Alpha Tau Medical - FDA Authorizes Two Additional U.S. Cancer Centers to Join Regain Trial

THOMSON REUTERS
·
Jun 11

Top Executive Makes Major Move With Alpha Tau Medical Stock

TIPRANKS
·
Jun 05

Alpha Tau Medical CFO Raphi Levy disposes of $352,606 in common shares

Reuters
·
Jun 05

Alpha Tau Medical Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 04

Alpha Tau Medical Is Maintained at Overweight by Barclays

Dow Jones
·
Jun 04

Alpha Tau Medical Ltd (DRTS) Receives a Buy from Barclays

TIPRANKS
·
Jun 04

Alpha Tau, Tolmar announce strategic collaboration agreement

TIPRANKS
·
Jun 03

Alpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy

MT Newswires Live
·
Jun 03

Alpha Tau, Tolmar partner to develop, commercialize Alpha DaRT for U.S. prostate cancer patients

Reuters
·
Jun 03

Alpha Tau Medical - Tolmar Granted Exclusive U.S. Rights for Prostate Cancer, Option for Bladder Cancer

THOMSON REUTERS
·
Jun 03

Alpha Tau Medical - Tolmar to Invest $15M in Manufacturing, $20M Equity at $11.99/Share, up to $161.5M in Milestones

THOMSON REUTERS
·
Jun 03

Alpha Tau Medical - to Manufacture Alpha Dart for Tolmar at 60% of Net Sales Price

THOMSON REUTERS
·
Jun 03

Alpha Tau Medical - up to $96.5M in Development and $65M in Commercial Milestone Payments Agreed

THOMSON REUTERS
·
Jun 03

Alpha Tau Medical Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 03

Alpha Tau Medical Reports Data Showing Alpha DaRT Increases Overall Survival for Patients With Pancreatic Cancer

MT Newswires Live
·
Jun 01

Alpha Tau reports 11.2-month median survival in pooled Phase I/II Alpha DaRT pancreatic cancer studies at ASCO 2026

Reuters
·
Jun 01

Alpha Tau Announces Strong Overall Survival Results From Alpha Dart® Pancreatic Cancer Studies Presented at 2026 Asco Annual Meeting

THOMSON REUTERS
·
Jun 01

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 01

Alpha Tau Medical Initiated at Overweight by Barclays

Dow Jones
·
May 28